BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/24/2026 6:01:13 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-02-05 01:25 |
|
Peer-Review Started |
|
2026-02-05 01:27 |
|
First Decision by Editorial Office Director |
|
2026-02-28 06:34 |
|
Return for Revision |
|
2026-02-28 06:34 |
|
Revised |
|
2026-03-01 12:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-02 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-02 05:02 |
|
Articles in Press |
|
2026-04-02 05:02 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-08-06 03:45 |
|
Publish the Manuscript Online |
|
2026-08-24 06:01 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: From discovery to application: Serum 5-hydroxytryptamine for early screening of Parkinson’s complications still faces key challenges
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ye-Xiang Chen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ye-Xiang Chen, Academic Fellow, PhD, Postdoctoral Fellow, Department of Pharmacology, College of Medicine, Jiaxing University, No. 899 Guangqiong Road, Jiaxing 314001, Zhejiang Province, China. yexiangchen@zcmu.edu.cn |
| Key Words |
Parkinson‘s disease; 5-hydroxytryptamine; Biomarker; Motor dysfunction; Depression |
| Core Tip |
Reduced serum 5-hydroxytryptamine levels may indicate an increased risk of both dyskinesia and depression in patients with Parkinson’s disease, suggesting its potential role as a unified screening marker for these complications. However, due to limited validation, as well as the absence of robust longitudinal data and standardized assessment protocols, its clinical applicability remains constrained. Therefore, it should be considered only as an adjunctive biomarker rather than a definitive diagnostic or prognostic indicator at the present stage. |
| Publish Date |
2026-08-24 06:01 |
| Citation |
Chen YX. Letter to the Editor: From discovery to application: Serum 5-hydroxytryptamine for early screening of Parkinson’s complications still faces key challenges. World J Psychiatry 2026; 16(9): 119768
|
| URL |
https://www.wjgnet.com/2220-3206/full/v16/i9/119768.htm |
| DOI |
https://doi.org/10.5498/wjp.119768 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
